Compare Nasdaq100 ETF (QQQ) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nasdaq100 ETF vs Sanofi SA — how do they compare? Nasdaq100 ETF trades at $751.4 (market cap $506.92B), while Sanofi SA trades at $40.04 (market cap $95.18B). The key difference: Nasdaq100 ETF is far larger — about 5.3× Sanofi SA's market cap, and Sanofi SA pays a 6.01% dividend while Nasdaq100 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nasdaq100 ETF for 162 Days and Sanofi SA for 94 Days on average.
| QQQ | SNY | |
|---|---|---|
Market Cap | $506.92B | $95.18B |
Volume | 48,326,518 | 2,995,646 |
52-Week High | $759.66 | $52.34 |
52-Week Low | $558.34 | $39.51 |
Typical Hold Time | 162 Days | 94 Days |
Sector | — | Health |
Enterprise Value | — | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QQQ trades at $750.47, down 0.96% on the day, with technical indicators showing a bullish trend supported by moving averages while oscillators remain neutral. The ETF faces mixed analyst sentiment with a 50/50 split between buy and sell recommendations. Recent news highlights QQQ's strong 10-year performance and ongoing innovation with new fund launches, though concerns about AI market valuations and interest rate impacts create headwinds.
The outlook remains cautiously optimistic given QQQ's tech-heavy exposure to AI growth trends, but elevated valuations and macroeconomic sensitivity present near-term risks. Long-term growth potential persists through innovation leadership, though investors should monitor concentration risk in technology holdings and market volatility around Fed policy decisions.
SNY trades at $40.17, down slightly by 0.07%. The technical outlook is bearish, with price near key support at $40. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21, and revenue for 2025 reached $46.72B. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling growth potential beyond its blockbuster drug Dupixent.
The stock presents a mixed outlook. Positive factors include consistent earnings beats, a high gross margin of 72.77%, and strategic partnerships. However, a bearish technical signal, a projected net income decline to $4.0B in 2026, and a high proportion of analyst hold ratings (51.86%) suggest caution. Key risks involve execution of new drug pipelines and future patent expirations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nasdaq100 ETF
The ETF is designed to track the performance of the securities and the stocks in the NASDAQ-100 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on QQQ →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
